Category: News

pH Pharma, biotech, announced that collaboration and licensing agreement for ADC development made with Immunome, U.S. biotech (For more information, please refer to the link below)http://www.biospectator.com/view/news_view.php?varAtcId=9127

pH Pharma, biotech, announced that collaboration and licensing agreement for ADC development made with Immunome, U.S. biotech (For more information, please refer to the link below)http://m.mtn.co.kr/news/news_view.php?id=2019101715184816599

Hoyoung Huh, CEO of pH Pharma, which is targeting to go IPO onto KOSDAQ through special listing for tech company, gave the keynote speech at the Biomedical Innovation Summit held in Madrid, Spain.(For more information, please refer to the link below)http://news.mt.co.kr/mtview.php?no=2019071514344805346

 To be a global healthcare company based both in Korea and U.S. through a shortening period of new drug development is pH Pharma’s goal. Hitnews went through pH Pharma from the date of foundation to the current.(For more information, please refer to the link below) http://www.hitnews.co.kr/news/articleView.html?idxno=8045

PH Pharma, which develops a treatment for glaucoma and non-alcoholic steatohepatitis (NASH), is conducting a pre-IPO (attracting funds before listing) worth 15 billion won. It is a form of large-scale purchase of new stocks (including preferred stocks) by domestic securities companies and management companies. The final goal is to be...

Over 20 bio ventures in progress of IPO… KRX supports bio listing  (For more information, please refer to the link below)http://news.mt.co.kr/mtview.php?no=2019012814232589614&type=1

“Target to complete tech evaluation in first half… Expect licensing-out deal” Jaesik Kim, CEO, says(For more information, please refer to the link below)http://news.mt.co.kr/mtview.php?no=2019011514200854887&type=1